A Seeking Alpha contributor expects the Food and Drug Administration to approve Chelsea Therapeutics International Ltd.'s (Nasdaq: CHTP) symptomatic neurogenic hypotension in Parkinson's disease treatment Northera. Shares of the pharmaceutical rose 16 cents to close at $2.00.
Chelsea Therapeutics' Northera Expected To Be Approved
March 27, 2013 at 17:26 PM EDT
